ACAD vs AMGN · P/E 15, rev $576.0M vs P/E 24, rev $10.05B
ACADIA Pharmaceuticals Inc (ACAD) versus Amgen Inc (AMGN) — a side-by-side from cached financials, not a winner call.
ACADIA Pharmaceuticals Inc (ACAD) is a biotechnology company listed on US.
Amgen Inc (AMGN) is a drug manufacturers - general company listed on US.
Latest reported ACAD revenue for 2026-06-30 was $576.0M. Net income was $35.1M. ACAD currently screens at market cap $3.51B and trailing P/E 15.3.
Latest reported AMGN revenue for 2026-06-30 was $10.05B. Net income was $2.38B. Revenue was up 16.7% from 2026-03-31 to 2026-06-30. AMGN currently screens at market cap $188.67B and trailing P/E 24.3.
ACAD currently screens at market cap $3.51B and trailing P/E 15.3. AMGN currently screens at market cap $188.67B and trailing P/E 24.3.
Not investment advice. Open the ACAD and AMGN stock pages for the full models.
Not investment advice.